With 95% confidence intervals, lanifibranor has shown potential in improving both metabolic and hepatic health in MASLD via significant improvements in triglycerides, HDL cholesterol, insulin levels, and steatosis, regardless of the diabetes status of the patient [115]. The gene discussed is INS; the disease is steatosis.